课题基金 / 基金详情

RYR2-targeted Gene Therapies for Treating Catecholaminergic Polymorphic Ventricular Tachycardia

RYR2-targeted Gene Therapies for Treating Catecholaminergic Polymorphic Ventricular Tachycardia
用于治疗儿茶酚胺能多形性室性心动过速的 RYR2 靶向基因疗法
批准号:
461749
负责人:
Roberts Jason D
金额:
$77.74万
依托单位:
依托单位国家:
加拿大
项目类别:
Operating Grants
财政年份:
2022
资助国家:
加拿大
项目状态:
未结题
起止时间:
2022-03-01 至 2027-03-01

项目摘要

项目成果

Roberts Jason D的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a form of electrical heart disease that is associated with a risk of sudden death. The majority of CPVT patients have an abnormality in the RYR2 gene, whose protein product plays an important
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Calcium Release Deficiency Syndrome: Establishing a Clinical Diagnostic Test and an International Registry
  • 批准号:
    478350
  • 项目类别:
    Operating Grants
  • 资助金额:
    $78.02万
  • 财政年份:
    2023
  • 负责人:
    Roberts Jason D
  • 依托单位:
Prize 202203PJT - RYR2-targeted Gene Therapies for Treating Catecholaminergic Polymorphic Ventricular Tachycardia
  • 批准号:
    467980
  • 项目类别:
    Operating Grants
  • 资助金额:
    $2.19万
  • 财政年份:
    2022
  • 负责人:
    Roberts Jason D
  • 依托单位:
Targeted Therapy with Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Right Ventricular Cardiomyopathy (TARGETED-ARVC)
  • 批准号:
    466287
  • 项目类别:
    Operating Grants
  • 资助金额:
    $198.82万
  • 财政年份:
    2022
  • 负责人:
    Roberts Jason D
  • 依托单位:
Targeted Therapy with Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Right Ventricular Cardiomyopathy (TARGETED-ARVC)
  • 批准号:
    474600
  • 项目类别:
    Operating Grants
  • 资助金额:
    $49.71万
  • 财政年份:
    2022
  • 负责人:
    Roberts Jason D
  • 依托单位:
海外基金